PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement.

May 2, 2017 Amendment to October 2016 Note

As previously disclosed on a Current Report on Form 8-K filed
with the Securities and Exchange Commission, on October 28, 2016,
an accredited investor (the Investor) purchased from Pressure
BioSciences Inc., a Massachusetts corporation (the Company) a
Promissory Note in the aggregate principal amount of up to
$2,000,000 (the October Note) due and payable on the earlier of
October 28, 2017 (the October Maturity Date) or on the seventh
business day after the closing of a Qualified Offering (as
defined in the October Note). On May 2, 2017, the Company and the
Investor entered into Amendment Number 1 to the October Note (the
Amendment) to, among other provisions, increase the October Notes
aggregate principal amount to up to $3,000,000. As consideration
for this Amendment, the Company issued 500,000 shares of common
stock to the Investor (less than five percent (5%) of the
Companys shares of common stock outstanding as of May 2, 2017).
The October Maturity Date remains the same. Garden State
Securities, Inc. is acting as Placement Agent for this
transaction and is being paid eight percent (8%) of all principal
amounts advanced to this transaction.

The foregoing description of the Amendment does not purport to be
complete and is qualified in its entirety by the terms and
conditions of the Amendment. A copy of the Amendment is attached
hereto as Exhibit 10.1 and is incorporated herein by reference.

May 22, 2017 Note

On May 22, 2017, the Investor purchased from the Company a
Promissory Note in the principal amount of $630,000 (the May
Note), due and payable on July 3, 2017 (the July Maturity Date).
Although the Note is dated May 19, 2017, the transaction did not
close until May 22, 2017, when the Company received the $630,000
to the Note. On the July Maturity Date, in addition to paying the
principal amount in full, the Company will pay a guaranteed
amount of interest of $63,000 along with an origination fee of
$32,000. Garden State Securities, Inc. acted as Placement Agent
for this transaction and was paid a five percent (5%) commission
of the principal amount advanced to this transaction.

The foregoing description of the May Note does not purport to be
complete and is qualified in its entirety by the terms and
conditions of the May Note. A copy of the May Note is attached
hereto as Exhibit 10.2 and is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant.

Reference is made to the disclosure set forth under Item 1.01 of
this Current Report on Form 8-K (the Report), which disclosure is
incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

*filed herewith

About PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO)

Pressure BioSciences, Inc. is focused on solving the problems inherent in biological sample preparation. The Company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, such as approximately 35,000 pounds per square inch (psi) or greater to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources. Its laboratory instrument, the Barocycler, and its consumables product line, which include its Pressure Used to Lyse Samples for Extraction (PULSE) tubes, and other processing tubes, and application specific kits, such as consumable products and reagents, together make up its PCT Sample Preparation System (PCT SPS). The Company is also the distributor for the Constant Systems cell disruption equipment, parts, and consumables.

PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO) Recent Trading Information

PRESSURE BIOSCIENCES, INC. (OTCMKTS:PBIO) closed its last trading session down -0.021 at 0.227 with 77,250 shares trading hands.